CURLF Quote, Financials, Valuation and Earnings

MannKind has a net margin of -23.43% compared to Curaleaf Holdings's net margin of 16.79%. Curaleaf Holdings's return on equity of -19.62% beat MannKind's return on equity of --.

Curaleaf Holdings has a consensus price target of $4.37, signalling upside risk potential of 419.84%. On the other hand MannKind has an analysts' consensus of $10.29 which suggests that it could grow by 125.56%. Given that Curaleaf Holdings has higher upside potential than MannKind, analysts believe Curaleaf Holdings is more attractive than MannKind.

Curaleaf Holdings has a beta of 1.064, which suggesting that the stock is 6.366% more volatile than S&P 500. In comparison MannKind has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.364%.

Curaleaf Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings pays -- of its earnings as a dividend. MannKind pays out -- of its earnings as a dividend.

Curaleaf Holdings quarterly revenues are $331.1M, which are larger than MannKind quarterly revenues of $78.4M. Curaleaf Holdings's net income of -$77.6M is lower than MannKind's net income of $13.2M. Notably, Curaleaf Holdings's price-to-earnings ratio is -- while MannKind's PE ratio is 45.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings is 0.46x versus 4.48x for MannKind. Usually stocks with elevated PS ratios are considered overvalued.

Quantum-Si has a net margin of -23.43% compared to Curaleaf Holdings's net margin of -2778.61%. Curaleaf Holdings's return on equity of -19.62% beat Quantum-Si's return on equity of -42.63%.

Curaleaf Holdings has a consensus price target of $4.37, signalling upside risk potential of 419.84%. On the other hand Quantum-Si has an analysts' consensus of $3.38 which suggests that it could grow by 168.52%. Given that Curaleaf Holdings has higher upside potential than Quantum-Si, analysts believe Curaleaf Holdings is more attractive than Quantum-Si.

Curaleaf Holdings has a beta of 1.064, which suggesting that the stock is 6.366% more volatile than S&P 500. In comparison Quantum-Si has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Curaleaf Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quantum-Si offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings pays -- of its earnings as a dividend. Quantum-Si pays out -- of its earnings as a dividend.

Curaleaf Holdings quarterly revenues are $331.1M, which are larger than Quantum-Si quarterly revenues of $1.2M. Curaleaf Holdings's net income of -$77.6M is lower than Quantum-Si's net income of -$33.1M. Notably, Curaleaf Holdings's price-to-earnings ratio is -- while Quantum-Si's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings is 0.46x versus 59.00x for Quantum-Si. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -23.43% compared to Curaleaf Holdings's net margin of -60.08%. Curaleaf Holdings's return on equity of -19.62% beat Sarepta Therapeutics's return on equity of -20.94%.

Curaleaf Holdings has a consensus price target of $4.37, signalling upside risk potential of 419.84%. On the other hand Sarepta Therapeutics has an analysts' consensus of $96.72 which suggests that it could grow by 166.66%. Given that Curaleaf Holdings has higher upside potential than Sarepta Therapeutics, analysts believe Curaleaf Holdings is more attractive than Sarepta Therapeutics.

Curaleaf Holdings has a beta of 1.064, which suggesting that the stock is 6.366% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.846, suggesting its less volatile than the S&P 500 by 15.365%.

Curaleaf Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Curaleaf Holdings quarterly revenues are $331.1M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Curaleaf Holdings's net income of -$77.6M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Curaleaf Holdings's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings is 0.46x versus 1.80x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -23.43% compared to Curaleaf Holdings's net margin of 23.33%. Curaleaf Holdings's return on equity of -19.62% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Curaleaf Holdings has a consensus price target of $4.37, signalling upside risk potential of 419.84%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.30 which suggests that it could grow by 17.72%. Given that Curaleaf Holdings has higher upside potential than Vertex Pharmaceuticals, analysts believe Curaleaf Holdings is more attractive than Vertex Pharmaceuticals.

Curaleaf Holdings has a beta of 1.064, which suggesting that the stock is 6.366% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.511, suggesting its less volatile than the S&P 500 by 48.928%.

Curaleaf Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Curaleaf Holdings quarterly revenues are $331.1M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Curaleaf Holdings's net income of -$77.6M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Curaleaf Holdings's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings is 0.46x versus 9.92x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.